Fursultiamine

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Fursultiamine
Accession Number
DB08966
Type
Small Molecule
Groups
Approved
Description

Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

Structure
Thumb
Synonyms
Not Available
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aronamin GoldFursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1)Tablet, film coatedOralOASIS TRADING2018-11-20Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aronamin GoldFursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1)Tablet, film coatedOralOASIS TRADING2018-11-20Not applicableUs
Categories
UNII
05J61265PX
CAS number
804-30-8
Weight
Average: 398.543
Monoisotopic: 398.144632098
Chemical Formula
C17H26N4O3S2
InChI Key
JTLXCMOFVBXEKD-FOWTUZBSSA-N
InChI
InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+
IUPAC Name
N-[(2E)-5-hydroxy-3-[(oxolan-2-ylmethyl)disulfanyl]pent-2-en-2-yl]-N-[(6-imino-2-methyl-1,6-dihydropyrimidin-5-yl)methyl]formamide
SMILES
C\C(N(CC1=CN=C(C)NC1=N)C=O)=C(\CCO)SSCC1CCCO1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,016,380.

General References
  1. Kobayashi T, Notoya K, Nakamura A, Akimoto K: Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005 Jun;54(6):249-55. [PubMed:15973508]
External Links
PubChem Compound
3002119
PubChem Substance
310264929
ChemSpider
2273321
ChEBI
135636
ChEMBL
CHEMBL1740659
Wikipedia
Fursultiamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132U.S. Patent 3,016,380.
Predicted Properties
PropertyValueSource
Water Solubility0.156 mg/mLALOGPS
logP1.21ALOGPS
logP-0.89ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.45ChemAxon
pKa (Strongest Basic)12.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area98.01 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity120.32 m3·mol-1ChemAxon
Polarizability42.02 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydropyrimidines. These are compounds containing a hydrogenated pyrimidine ring (i.e. containing less than the maximum number of double bonds.).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Hydropyrimidines
Alternative Parents
Imidolactams / Tetrahydrofurans / Tertiary carboxylic acid amides / Heteroaromatic compounds / Organic disulfides / Sulfenyl compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary alcohols
show 5 more
Substituents
Hydropyrimidine / Imidolactam / Tertiary carboxylic acid amide / Tetrahydrofuran / Heteroaromatic compound / Carboxamide group / Organic disulfide / Carboxylic acid derivative / Dialkyl ether / Ether
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 09, 2014 09:23 / Updated on November 02, 2019 02:32